Virology-focused Enanta Pharmaceuticals, Inc. took a positive step in its two-mechanism approach to providing a treatment for respiratory syncytial virus (RSV) on 26 September as its RSV L-protein inhibitor EDP-323 succeeded in a Phase IIa challenge study of healthy volunteers. But analysts called upcoming Phase IIb data for the firm’s N-protein inhibitor zelicapavir in pediatric RSV patients potentially the greater inflection point for Enanta’s program.
Key Takeaways
-
Enanta, with two antivirals in mid-stage development to treat RSV infection, reported positive Phase IIa challenge data for its novel RSV L-protein inhibitor.
-
The...
On a same-day call, Enanta CEO Jay Luly asserted that the two Phase II candidates comprise “the leading portfolio of RSV treatments in development today.” While vaccines to prevent RSV...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?